Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States
Alexander C. Schmidt(GlaxoSmithKline (United States)), Stephen J. Thomas(Global Viral), Luis Javier Martínez-González(Walter Reed Army Institute of Research), Jean‐François Toussaint(Université Paris Cité), Kristopher Paolino(Walter Reed National Military Medical Center), Kenneth H. Eckels(Walter Reed Army Institute of Research), Alix Collard(GlaxoSmithKline (Belgium)), Edith Lepine(GlaxoSmithKline (United States)), Bruce L. Innis(Universidad de Los Andes, Chile), Richard G. Jarman(Walter Reed Army Institute of Research), Richard C. Ruck(Walter Reed Army Institute of Research), Leyi Lin(Walter Reed Army Institute of Research), Rafael De La Barrera(Walter Reed Army Institute of Research)
Cited by 67
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937
Rapid development of a DNA vaccine for Zika virus
|Science|2016|402
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
|New England Journal of Medicine|2015|390
Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments
|Journal of Virological Methods|2006|342